NCT03004261View on ClinicalTrials.gov

CMV-CTL for the Treatment of CMV Infection After HSCT

PHASE4CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Cytomegalovirus InfectionsHematological Disease
Interventions
BIOLOGICAL

donor derived cytomegalovirus specific T lymphocytes

donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.

DRUG

Foscarnet

Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.

DRUG

Ganciclovir

Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.

Trial Locations (1)

200080

Shanghai Jiao Tong University Affilated Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

INDUSTRY

lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03004261 - CMV-CTL for the Treatment of CMV Infection After HSCT | Biotech Hunter | Biotech Hunter